Skip to main content
OpenTrials

Clinical trial condition

Esophageal Squamous Cell Carcinoma (ESCC)

Explore clinical trials studying Esophageal Squamous Cell Carcinoma (ESCC). Study availability and eligibility vary by location and protocol.

61 public trials 23 recruiting studies
Refine in advanced search Browse all conditions

Esophageal Squamous Cell Carcinoma (ESCC) trial results

Completed

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

NCT04210115

Conditions
Adenocarcinoma Of Esophagus, Carcinoma, Carcinoma, Squamous Cell, +17 more
Locations
  • MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691) Long Beach, California, United States
  • Columbus Regional Research Institute ( Site 0047) Columbus, Georgia, United States
  • University of Kansas Cancer Center ( Site 0023) Westwood, Kansas, United States
  • Cancer Center of Kansas ( Site 0058) Wichita, Kansas, United States
View all 170 locations
View Trial Details
Completed

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

NCT03957590

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
Locations
  • Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Chongqing Cancer Hospital Chongqing, Chongqing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
View all 33 locations
View Trial Details
Completed

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

NCT05342636

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +14 more
Locations
  • Liga Norte Riograndense Contra o Câncer ( Site 2303) Natal, Rio Grande do Norte, Brazil
  • Hospital Nossa Senhora da Conceição ( Site 2301) Porto Alegre, Rio Grande do Sul, Brazil
  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300) São Paulo, Brazil
  • FALP-UIDO ( Site 2400) Santiago, Region M. de Santiago, Chile
View all 46 locations
View Trial Details
Completed

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

NCT03708328

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +35 more
Locations
  • Columbia Univ Med Ctr New York, United States
  • MD Anderson Cancer Center Houston, Texas, United States
  • Herlev Hospital Herlev, Denmark
  • Rigshospitalet København Ø, Denmark
View all 17 locations
View Trial Details
Completed

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

NCT03783442

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
Locations
  • Smilow Cancer Hospital At Yale New Haven, Connecticut, United States
  • Renovatio Clinical The Woodlands, Texas, United States
  • Coffs Harbour Base Hospital Coffs Harbour, New South Wales, Australia
  • St Vincents Hospital Melbourne Fitzroy, Victoria, Australia
View all 124 locations
View Trial Details
Completed

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

NCT03430843

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +17 more
Locations
  • Henry Ford Hospital Detroit, Michigan, United States
  • Toledo Clinic Cancer Center Toledo, Ohio, United States
  • Imelda Ziekenhuis Bonheiden Bonheiden, Belgium
  • Cliniques Universitaires Saint Luc Brussels, Belgium
View all 104 locations
View Trial Details

Related conditions